KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Financing Activities (2018 - 2025)

Moderna (MRNA) has disclosed Cash from Financing Activities for 8 consecutive years, with $581.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 19466.67% to $581.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $593.0 million through Dec 2025, up 958.93% year-over-year, with the annual reading at $593.0 million for FY2025, 958.93% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $581.0 million at Moderna, up from -$1.0 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $581.0 million in Q4 2025, with the low at -$1.3 billion in Q2 2022.
  • Average Cash from Financing Activities over 5 years is -$252.4 million, with a median of -$13.5 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities plummeted 51950.0% in 2022, then skyrocketed 19466.67% in 2025.
  • Over 5 years, Cash from Financing Activities stood at -$873.0 million in 2021, then skyrocketed by 49.83% to -$438.0 million in 2022, then surged by 75.11% to -$109.0 million in 2023, then soared by 97.25% to -$3.0 million in 2024, then surged by 19466.67% to $581.0 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $581.0 million, -$1.0 million, and $9.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.